Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of Orally Administered BX002-A in Healthy Adult Individuals

Trial Profile

A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of Orally Administered BX002-A in Healthy Adult Individuals

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BX 002 (Primary) ; Esomeprazole
  • Indications Inflammatory bowel diseases; Primary sclerosing cholangitis
  • Focus Adverse reactions; First in man
  • Sponsors BiomX

Most Recent Events

  • 15 Nov 2021 Results assessing the safety and tolerability of orally administered BX002-A cocktail of bacteriophages targeting KP2H7 and assessed phage viability after passage through the gastrointestinal tract, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
  • 03 Feb 2021 Status changed from active, no longer recruiting to completed.
  • 02 Feb 2021 According to a BiomX media release, Phase 1b/2 trial of BX003 for the reduction of K. pneumonia will start based on data from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top